28 November 2012 EMA/CHMP/703852/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report Lyxumia International non-proprietary name: lixisenatide Procedure No. EMEA/H/C/002445/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 5 1.1. Submission of the dossier ...................................................................................... 5 1.2. Manufacturers ...................................................................................................... 6 1.3. Steps taken for the assessment of the product ......................................................... 6 2. Scientific discussion ................................................................................ 7 2.1. Introduction......................................................................................................... 7 2.2. Quality aspects .................................................................................................... 8 2.2.1. Introduction ...................................................................................................... 8 2.2.2. Active Substance ............................................................................................... 8 2.2.3. Finished Medicinal Product ................................................................................ 10 2.2.4. Discussion on chemical, pharmaceutical and biological aspects .............................. 14 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 14 2.2.6. Recommendation for future quality development ................................................. 14 2.3. Non-clinical aspects ............................................................................................ 14 2.3.1. Introduction .................................................................................................... 14 2.3.2. Pharmacology ................................................................................................. 14 2.3.3. Pharmacokinetics............................................................................................. 15 2.3.4. Toxicology ...................................................................................................... 15 2.3.5. Ecotoxicity/environmental risk assessment ......................................................... 17 2.3.6. Discussion on non-clinical aspects...................................................................... 17 2.3.7. Conclusion on the non-clinical aspects ................................................................ 18 2.4. Clinical aspects .................................................................................................. 18 2.4.1. Introduction .................................................................................................... 18 2.4.2. Pharmacokinetics............................................................................................. 21 2.4.3. Pharmacodynamics .......................................................................................... 25 2.4.4. Discussion on clinical pharmacology ................................................................... 27 2.4.5. Conclusions on clinical pharmacology ................................................................. 29 2.5. Clinical efficacy .................................................................................................. 29 2.5.1. Dose response studies...................................................................................... 29 2.5.2. Main studies ................................................................................................... 30 2.5.3. Discussion on clinical efficacy ............................................................................ 55 2.5.4. Conclusions on the clinical efficacy ..................................................................... 57 2.6. Clinical safety .................................................................................................... 57 2.6.1. Discussion on clinical safety .............................................................................. 65 2.6.2. Conclusions on the clinical safety ....................................................................... 67 2.7. Pharmacovigilance .............................................................................................. 67 2.8. User consultation ............................................................................................... 76 3. Benefit-Risk Balance ............................................................................ 76 4. Recommendations ............................................................................... 80 Lyxumia CHMP assessment report Page 2/81 List of abbreviations ADR adverse drug reaction AE adverse event ANCOVA analysis of covariance ARAC allergic reaction assessment committee AUC area under the concentration curve BID twice daily bpm beats per minute CAC Cardiovascular Events Adjudication Committee CHMP Committee for Medicinal Products for Human Use CI confidence interval CL clearance CLCR creatinine clearance CLR renal clearance Cmax maximum concentration CSR clinical study report CV cardiovascular DPP•4 dipeptidyl peptidase-4 ECG electrocardiogram EMA European Medicines Agency FPG fasting plasma glucose GBEF gall bladder ejection fraction GCP Good Clinical Practice GLP-1 glucagon-like peptide 1 HbA1c glycosylated hemoglobin HLGT high level group term HLT high level term ICH International Conference on Harmonisation LLOQ lower limit of quantification LOCF last observation carried forward LS mean least squares mean MAA marketing authorization application MACE major adverse cardiac events MAT mean absorption time MI myocardial infarction mITT modified intent-to-treat OC oral contraceptive PD pharmacodynamic(s) PK pharmacokinetic(s) PNWT predicted normal weight PPG postprandial plasma glucose PT preferred term QD once daily SAE serious adverse event SU sulfonylurea TEAE treatment emergent adverse event T2DM type 2 diabetes mellitus Lyxumia CHMP assessment report Page 3/81 TZD thiazolidinedione Lyxumia CHMP assessment report Page 4/81 1. Background information on the procedure 1.1. Submission of the dossier The applicant sanofi-aventis groupe submitted on 27 October 2011 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Lyxumia, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 23 November 2010. The applicant applied for the following indication: Lyxumia is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in patients not adequately controlled on oral antidiabetics and/or basal insulin: In combination with the following oral antidiabetics: - metformin, - a sulphonylurea, or - a combination of metformin and a sulphonylurea, In combination with a basal insulin: - alone, - in combination with metformin, or - in combination with a sulphonylurea. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application. The application submitted is composed of administrative information, complete quality data, non- clinical and clinical data based on applicants’ own tests and studies. Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/225/2011 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/225/2011 was not yet completed as some measures were deferred. Information relating to orphan market exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication. New active Substance status The applicant requested the active substance lixisenatide contained in the above medicinal product to be considered as a new active substance in itself. Lyxumia CHMP assessment report Page 5/81 Scientific Advice The applicant received Scientific Advice from the CHMP on 15 November 2007 (including clarifications on 18 January 2008) and on 24 June 2010. The Scientific Advice pertained to quality, non-clinical and clinical aspects of the dossier. Licensing status The product was not licensed in any country at the time of submission of the application. 1.2. Manufacturers Manufacturer responsible for batch release Sanofi-Aventis Deutschland GmbH Brüningstrasse 50, Industriepark Höchst 65926 Frankfurt am Main Germany 1.3. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Kristina Dunder Co-Rapporteur: Walter Janssens CHMP Peer reviewers: Pieter de Graeff and Agnes Gyurasics The application was received by the EMA on 27 October 2011. The